SiBone SIBN

SI-BONE held its Q2 2026 earnings call, covering financial results, operational updates, and future outlook for the company. Q2 2026 earnings figures and guidance from the call can substantially move SiBone's stock and investor outlook.

SI-BONE Inc reported strong revenue growth for Q2 2026 and raised its financial guidance. Strong revenue growth and raised guidance indicate substantial positive developments for SI-BONE's financial trajectory and investor confidence.

SI-BONE held Q2 2026 earnings call covering financial results and business outlook. Quarterly earnings calls deliver results and guidance that move near-term stock prices and sentiment.

SI-BONE reported second quarter 2026 financial results and raised its 2026 guidance. Raised 2026 guidance signals stronger expected performance and positive momentum.

Si-Bone posted a Q2 net loss but exceeded revenue estimates. Q2 earnings with a loss yet revenue beat point to moderate short-term effects on valuation and sentiment.

SiBone reported Q2 results with revenue of $34.1M, up 20% YoY, driven by U.S. adoption of iFuse and international expansion. Gross margin reached 82%. Company raised full-year revenue guidance to $138-140M and highlighted new product launches plus surgeon training progress. Management noted continued focus on penetrating the SI joint fusion market while managing operating expenses. Q2 results and raised guidance provide moderate visibility into revenue trajectory and adoption trends but do not signal transformative strategic shifts.

SiBone (SIBN) stock soared almost 20% on Tuesday due to positive developments driving investor enthusiasm. A nearly 20% one-day stock surge signals major positive news likely to significantly influence SiBone's future performance and market trajectory.

SI-BONE Inc (SIBN) reported strong Q1 2026 revenue growth and raised full-year guidance in its earnings call. Strong revenue growth and raised guidance boost financial outlook and investor sentiment significantly.

SI-BONE reported Q1 2026 financial results and outlook during its earnings call. Quarterly earnings and guidance directly shape near-term investor views on revenue trajectory.

SI-Bone (SIBN) released its Q1 2026 earnings call transcript detailing financial results, management discussion, and analyst Q&A. Q1 2026 earnings transcript discloses financial performance, strategic updates, and guidance significantly influencing SIBN's trajectory and investor sentiment.

SI-BONE, Inc. reported strong first-quarter 2026 financial results, including revenue growth, and raised its full-year 2026 guidance, signaling improved outlook. Raising full-year guidance after solid Q1 results points to accelerated growth and enhanced investor confidence.

SiBone released highlights from its Q1 earnings call, covering financial results, operational updates, and forward guidance. Q1 earnings call highlights provide moderately noticeable updates on financial performance and outlook, influencing investor sentiment without fundamental changes.

Si-Bone (SIBN) reported a Q1 net loss but exceeded revenue estimates. Revenue beat despite Q1 loss signals moderately noticeable influence on financial performance.

SI-BONE (SIBN) Q4 2025 earnings call covered financial results, revenue growth, product performance, and 2026 guidance. Q4 earnings summary reveals key financial metrics and forward guidance directly shaping SIBN's market trajectory and investor outlook.

Smith+Nephew partners with SI-BONE to distribute the iFuse TORQ portfolio, expanding access to SI-BONE's spinal fusion technology through Smith+Nephew's global sales network. Partnership with Smith+Nephew provides SI-BONE significant distribution expansion for its flagship iFuse TORQ product, likely driving revenue growth and market penetration.

SI-BONE Inc (SIBN) reported record Q4 2025 revenue and announced strategic partnerships in earnings call highlights. Record revenue reflects strong financial growth and strategic partnerships enhance competitive positioning and long-term prospects.

SiBone released Q4 earnings call highlights, covering financial results, revenue growth, product updates, and forward guidance. Q4 earnings highlights detail financial performance and strategic outlook, likely driving significant stock volatility and investor reassessment.

SiBone (SIBN) released Q4 earnings snapshot detailing financial results. Q4 earnings snapshot provides critical financial data impacting investor sentiment and stock trajectory.

Smith+Nephew signs distribution agreement with SI-BONE. Distribution deal with major medtech firm Smith+Nephew boosts SI-BONE's sales channels and market expansion.

SI-BONE, Inc. reported record financial results for Q4 2025 and issued 2026 guidance. Record Q4 results and forward guidance represent major positive financial developments likely to significantly influence stock performance and investor sentiment.

SiBone (SIBN) reported a Q4 net loss but exceeded revenue estimates. Q4 revenue beat tempers the net loss impact on financial performance and market sentiment.

Si-Bone (SIBN) Q4 earnings expected to decline amid preview analysis. Expected Q4 earnings decline impacts financial performance and short-term market sentiment.

SI-BONE announced preliminary revenue figures for the fourth quarter and full year 2025, indicating strong financial performance and growth in its business operations. The company highlighted key drivers behind the revenue increase, including successful product adoption and market expansion efforts. These results reflect the ongoing demand for SI-BONE's innovative solutions in the orthopedic market, positioning the company favorably for future growth. Strong revenue growth signals significant market demand and potential for future performance improvements.

SiBone (SIBN) has gained attention following endorsements from Jim Cramer and new analyst coverage, prompting discussions about its valuation. The endorsements may enhance market sentiment and investor interest, potentially impacting the company's stock performance. Analysts are now evaluating SIBN's growth prospects and market position in light of these developments. Endorsements and new analyst coverage are likely to significantly influence investor sentiment and market dynamics for SiBone.

SiBone (SIBN) has been tagged by Jim Cramer as a 'Great, Great Speculation,' which raises questions about the company's risk narrative and niche thesis. This designation could influence investor sentiment and market perception, potentially impacting SiBone's future performance and strategic positioning in the orthopedic market. Cramer's speculation tag may moderately influence market sentiment and investor interest in SiBone's operations.

Jim Cramer highlighted SiBone (SIBN) as a strong speculative investment, emphasizing its potential in the market. He noted the company's innovative approach to treating sacroiliac joint dysfunction and expressed confidence in its growth prospects. Cramer encouraged investors to consider SIBN as a worthwhile addition to their portfolios, particularly for those willing to take on higher risks for potential rewards. Cramer's endorsement suggests significant investor interest and potential market movement for SiBone.

SiBone (SIBN) has delivered a 40% return to investors over the past year, reflecting positive market sentiment and performance. The company's innovative solutions in the orthopedic sector continue to attract attention, contributing to its favorable stock performance. Analysts suggest that this growth may be indicative of strong demand for SiBone's products and services, positioning the company well for future opportunities. The significant return on investment indicates strong market performance and potential for continued growth in the orthopedic sector.

SiBone (SIBN) has been added to Needham's 'Conviction List' and named a '2026 Top Pick', indicating strong confidence in the company's future performance and growth potential. This recognition is expected to enhance investor sentiment and could positively influence the stock's market performance. Inclusion in Needham's 'Conviction List' and designation as a 'Top Pick' suggest significant positive market sentiment and potential for future growth.

SiBone (SIBN) has recently experienced a golden cross, a technical indicator suggesting potential bullish momentum. Analysts are evaluating whether this signals a good buying opportunity for investors. The company's performance and market sentiment are under scrutiny as it navigates its growth trajectory in the medical technology sector. The golden cross indicates potential positive momentum, but its long-term impact on SiBone's performance remains uncertain.

SiBone (SIBN) experienced a significant surge in stock price due to positive developments in its business operations and market performance. The company reported strong sales figures and announced new partnerships that are expected to enhance its market position. Investors reacted favorably, driving the stock higher as analysts expressed optimism about the company's growth trajectory and potential for future profitability. Strong sales figures and new partnerships are likely to significantly impact SiBone's future performance and market position.